# A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

> **NCT03818607** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 42 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** ABP 959
- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT03818607
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-22
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-07-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03818607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03818607, "A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03818607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*